CMOs to continue picking up Big Pharma non-core facilities
Recent facility acquisitions by Lonza and Catalent show Big Pharma is divesting its non-core assets in a trend that is set to continue, according to PharmSource. In the previous couple of months, contract manufacturing organizations (CMOs) Lonza and Catalent have both increased their production n ...
With potentially three acquisitions within nine months, Agilent Technologies has rapidly grown its presence in the cell analysis space and says i ...
Another quarter of deal making by Dyadic International demonstrates how companies are looking to microorganisms instead of CHO to produce afforda ...
Orchard Therapeutics says it will balance its existing CMO network with a planned facility in Fremont to create the infrastructure needed to comm ...
Sartorius Stedim Biotech says its newly launched mammalian cell bank manufacturing offering fits hand-in-hand with its existing cell line develop ...
Recent Tweets
-
@Dan5tanton: @bobby_gaspar of @orchard_tx confirms that design work is “well under way” for its CA site and that th… https://t.co/BKfCoAbqGI
2 hours ago
-
A growing number of Big Pharma companies are abandoning diversification strategies and divesting non-core assets, l… https://t.co/viq22QNYZt
4 days ago
-
@Informa_LS is launching one of the biggest surveys of cell and #genetherapy professionals around the world on ana… https://t.co/8JSZXJl8s8
7 days ago
-
RT @Dan5tanton: Momenta says planned runs at manufacturing partner GSK could be reattributed to another product as it ends developm… https://t.co/vTUtW0H7CK
1 week ago
Trending
Multimedia
China's Emergence in Global Biopharma Manufacturing: Trends in the Chinese Biopharma Industry
BPI Theater @ BIO 2019
GE Healthcare Working to Overcome Advanced Therapy Manufacturing Difficulties
BPI Theater @ BIO 2019
Sartorius's Bioanalytics Seeing High Return from Cambridge Biotech
Industry Innovators 2019-2020
Advancing Robust Manufacture of T-Cell Therapies: Application of Single-Use Stir-Tank Bioreactors